Amundi
ADPT icon

Amundi’s Adaptive Biotechnologies ADPT Stock Holding History

Amundi’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Sell
10,419
-268
-3% -$4.11K ﹤0.01% 1940
2026
Q1 		$148K Buy
+10,687
New +$170K ﹤0.01% 1922
2025
Q2 		– Sell
-4,531
Closed -$33.6K – 1663
2025
Q1 		$33.6K Sell
4,531
-11,001
-71% -$84.6K ﹤0.01% 1837
2024
Q4 		$104K Buy
15,532
+4,531
+41% +$25K ﹤0.01% 1789
2024
Q3 		$57.8K Buy
+11,001
New +$47.9K ﹤0.01% 1831
2024
Q2 		– Sell
-43,930
Closed -$103K – 1922
2024
Q1 		$103K Hold
43,930
– – ﹤0.01% 1761
2023
Q4 		$204K Sell
43,930
-37,027
-46% -$169K ﹤0.01% 1628
2023
Q3 		$347K Buy
80,957
+25,502
+46% +$169K ﹤0.01% 1475
2023
Q2 		$370K Buy
55,455
+35,321
+175% +$263K ﹤0.01% 1451
2023
Q1 		$170K Sell
20,134
-58
-0.3% -$511 ﹤0.01% 1611
2022
Q4 		$190K Buy
20,192
+953
+5% +$7.42K ﹤0.01% 1523
2022
Q3 		$150K Buy
19,239
+9,133
+90% +$86K ﹤0.01% 1496
2022
Q2 		$97K Buy
+10,106
New +$88.9K ﹤0.01% 1448

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Amundi's ADPT Position: Q2 2026 in Review

Amundi reduced its Adaptive Biotechnologies (ADPT) stake by 2.5% in Q2 2026, selling an estimated $4.11K and leaving 10,419 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #1940.

Amundi first reported a position in ADPT in Q2 2022 and has held it in 13 quarters since. The position peaked at $370K in Q2 2023. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Amundi held 10,419 shares of Adaptive Biotechnologies worth $223K as of Q2 2026.
  • Amundi sold 268 Adaptive Biotechnologies shares in Q2 2026, an estimated $4.11K.
  • Adaptive Biotechnologies made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1940 holding.
  • Amundi first reported a position in Adaptive Biotechnologies in Q2 2022 and has held it in 13 quarters since.
  • Amundi's Adaptive Biotechnologies position peaked at $370K in Q2 2023.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.